

Freedom of Information Request: Our Reference CTMUHB_389_21

You asked:

I am analysing the treatment of neurology patients within secondary care. Could you please answer the following three questions:

Q1. How many patients have been treated with the following drugs in the past 4 months:

- **Aimovig (erenumab) - any disease**
- **Ajovy (fremanezumab) - any disease**
- **Emgality (galcanezumab) - any disease**
- **Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY**

Please find below a table populated with the data recorded by Medicines Management during the period of May 21 to August 21 as requested.

Medicine	Number of Patients
Aimovig (erenumab) - any disease	0
Ajovy (fremanezumab) - any disease	5
Emgality (galcanezumab) - any disease	**
Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY	83

Please note the following:

- The figure provided for the use of Botulinum Toxin relates to any condition. This is because our Medicines Management systems do not record the condition being treated. The specific information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.
- Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2)

of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality) for migraine (Y/N)?

Yes.

Q3. How many patients have been treated in the past 4 months for the following conditions:

- **Chronic migraine (15+ headache days per month)**
- **Episodic migraine (4-14 headache days per month)**

Our Patient Administrative Systems do not differentiate between episodic and chronic migraines under the Headache Service.

Therefore, we can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.